Patent · US Active

Nucleic acids encoding polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP

US12384840B2 · kind B2 · utility

0Cited by

1References

16Claims

0Family size

Assignees

Ablynx N.V. · BE
Sanofi · FR

Inventors

Heidi Rommelaere · Wondelgem, BE
Ann Brigé · Ertvelde, BE
Sigrid Cornelis · Gent, BE
Bruno Dombrecht · Heusden, BE
Eric Lorent · Zwijnaarde, BE
Melanie Rieger · Zwijnaarde, BE
Timothy Soos · Boston, US
John Park · Warthausen, DE
Bernd Weigle · Ingelheim am Rhein, DE
Klaus Erb · Mittelbiberach, DE

Key dates

Filing date	Nov 19, 2021
Grant date	Aug 12, 2025
Priority date	—
Expiry date	Mar 8, 2044

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.